Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rekah Pharmaceutical ProdXTAE:REKA 57 Median PS Value is ₪27.57 as of Jul. 14, 2026, which is 100% below its 10-year median of 0.42. GuruFocus rates XTAE:REKA with a GF Score™ of 57/100 and a GF Value™ of ₪13.05 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 544 Drug Manufacturers companies, Rekah Pharmaceutical Prod ranks better than 89.15% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Rekah Pharmaceutical Prod's Median PS Value or its related term are showing as below:
XTAE:REKA'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37 Med: 0.42 Max: 0.42
Current: 0.37
During the past 13 years, the highest Price to Median PS Value of Rekah Pharmaceutical Prod was 0.42. The lowest was 0.37. And the median was 0.42.
XTAE:REKA's Price-to-Median-PS-Value is ranked better than 89.15% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.875
vs XTAE:REKA: 0.37
Rekah Pharmaceutical Prod (XTAE:REKA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Rekah Pharmaceutical Prod's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
10.30
/
27.57
=
0.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rekah Pharmaceutical Prod Median PS Value Related Terms
Rekah Pharmaceutical Prod Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:REKA vs ZTS, UTHR, VTRS: Median PS Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rekah Pharmaceutical Prod Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Rekah Pharmaceutical Prod's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.0238.
Rekah Pharmaceutical Prod's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪26.928.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rekah Pharmaceutical Prod (XTAE:REKA) has a Median PS Value of ₪27.57 as of Jul. 14, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Rekah Pharmaceutical Prod and its competitors. This is 6464% above median its historical median of 0.42. Over the past decade, Rekah Pharmaceutical Prod's Median PS Value has ranged from 0.37 to 0.42. According to the industry distribution chart, Rekah Pharmaceutical Prod ranks #59 out of 544 companies in the Drug Manufacturers industry, placing it in the top 10.8%.
Is Rekah Pharmaceutical Prod's Median PS Value too high?
Rekah Pharmaceutical Prod's current Median PS Value of ₪27.57 is 6464% above median its 10-year median of 0.42. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 0.42. Based on the distribution chart, Rekah Pharmaceutical Prod ranks #59 out of 544 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rekah Pharmaceutical Prod has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rekah Pharmaceutical Prod's Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rekah Pharmaceutical Prod ranks #59 out of 544 companies for Median PS Value. This places Rekah Pharmaceutical Prod in the top 11% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.88. Historically, Rekah Pharmaceutical Prod's own Median PS Value has ranged from 0.37 to 0.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.88, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Rekah Pharmaceutical Prod and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rekah Pharmaceutical Prod's current Median PS Value is ₪27.57, which is 6464% above median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rekah Pharmaceutical Prod stock overvalued right now?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod (XTAE:REKA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪13.05, compared to a current price of ₪10.30 — trading 21.1% below its estimated fair value. The current Median PS Value is ₪27.57, which is 6464% above median its 10-year median of 0.42. Rekah Pharmaceutical Prod's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Rekah Pharmaceutical Prod (XTAE:REKA), the current Median PS Value is ₪27.57 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rekah Pharmaceutical Prod (XTAE:REKA) Overvalued in 2026?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod stock appears to be undervalued.
The current stock price of ₪10.30 is trading 21.1% below its estimated GF Value™ of ₪13.05.
GuruFocus considers Rekah Pharmaceutical Prod to be Modestly Undervalued.
Key valuation signals for XTAE:REKA:
Median PS Value: ₪27.57 (6464% above median its 10-year median of 0.42)
GF Value™: ₪13.05 vs. price of ₪10.30 (21.1% below fair value)
No single metric tells the full story. See the XTAE:REKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.
57GF Score
Get the complete analysis for XTAE:REKA
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:REKA has been successfully added to your 
